Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.
about
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in CancerRecent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingUtilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy DeliveryCan nanomedicines kill cancer stem cells?Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive systemDrug Carriers: Not an Innocent Delivery ManCan nanotechnology potentiate photodynamic therapy?Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice.Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures.CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: a novel hyaluronic acid-based drug delivery system.Scalable manufacture of built-to-order nanomedicine: spray-assisted layer-by-layer functionalization of PRINT nanoparticles.Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes.CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapyImmunological treatment options for locoregionally advanced head and neck squamous cell carcinomaThe role of breast cancer stem cells in metastasis and therapeutic implications.Fluorescent liposomes for differential interactions with glycosaminoglycans.Hyaluronan-CD44 interactions as potential targets for cancer therapy.Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapySynergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.Cell-specific optoporation with near-infrared ultrafast laser and functionalized gold nanoparticles.A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?Probable biofilm formation in the cheek as a complication of soft tissue filler resulting from improper endodontic treatment of tooth 16.A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo.Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells.Hyaluronic Acid Conjugated Magnetic Prussian Blue@Quantum Dot Nanoparticles for Cancer Theranostics.Protective influence of hyaluronic acid on focal adhesion kinase activity in human skin fibroblasts exposed to ethanolApplication of Collagen-Model Triple-Helical Peptide-Amphiphiles for CD44-Targeted Drug Delivery Systems.Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate.Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumorsAntitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminaseImpact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent"Marker of Self" CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumorsOverview of the role of nanotechnological innovations in the detection and treatment of solid tumors.A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44.Therapeutic applications of hyaluronan.Chemoenzymatic synthesis of oligohyaluronan-lipid conjugates.Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer.Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systemsPolysaccharides as building blocks for nanotherapeutics.
P2860
Q26747319-493E0ED7-7CEF-4C50-956A-BF51CE96A5DFQ26778234-379CDA6D-3329-494F-AEED-D3A68AB271CFQ26786070-A0F18A30-20F0-4D46-A70C-D18C31755827Q27022017-CE17CBD8-D351-4E1A-860F-96B1CEDD8DD2Q28079367-1C316BD6-FC7D-48AC-BE72-5B545E706AB0Q28082414-43140AF0-AEDC-4523-A97A-9D4C882F41E7Q28388084-95330CF6-C42E-404E-BAED-D9E5B38DB15BQ30436623-2E2B43A1-7C1C-40E7-B68F-47ACBB1F986FQ30607164-8609B05F-E278-4CBC-9565-AF29F8ADCC13Q30738016-6EF904AD-32C3-4E3B-AD00-25898A38BB74Q33693448-E28C1EBF-16BA-49D6-9EC9-2480B8C717E5Q33709840-78CF1214-E0CD-4C72-8C09-426C5AC6C2ACQ33811463-026D4C70-34EB-425B-B004-C7B4FDB3BF05Q33993634-0179BC5F-A04E-4EAA-9EAB-61B8B0E8F106Q34181954-193891F9-2426-4602-B53F-DD911B19AC6AQ35070157-D67F938F-55E1-4FF4-B15D-6BCB5019E493Q35136625-0C18368B-B733-414F-A8C6-FB0CEE0E91CEQ35194441-B2214829-3FCF-4AAA-BDE1-F9E248C21B84Q35746919-D7F66C9E-A684-4984-86D6-4EC452D5728AQ35751958-97817DCF-C596-46E3-846A-99C91C76F396Q35804266-99F3A793-9FCC-48A3-BFE9-1F662A6B6339Q35823840-58B0CB5F-9F0D-45D4-82B2-CD50D9CCE531Q35972697-CAF3CBE6-692F-480A-8F77-56DCAF8A4213Q36061347-B8E7CF92-71F7-4C4D-8BBE-DABBFC021D3AQ36072049-EBC8E438-0C4D-4187-B592-BFDAF497F07CQ36296095-09D27FBE-B154-4852-B121-79BF4DB96F7BQ36307952-261F0C88-CF11-4C6E-B6A4-949682E55913Q36421268-5D964D33-C69E-4F90-9EB9-292D19AAF03CQ36755506-F884ECD1-66E1-4C9D-8F1E-3B641BD6C891Q36795709-564BDDEC-7114-4D0B-B00F-E4ECB8588396Q37251338-7F89DC4D-2A35-456C-840F-7F042DEFCD34Q37327825-C8FD8218-0C31-4573-8393-6C2F160208F6Q37490583-1F483EFA-90C6-4380-BB5F-4FCCD3FE7948Q37525035-C704BFA4-64A0-4C1E-AB89-D790BF41AFF9Q37690517-30C2785B-0FC8-431B-BB1C-8ECB32DAB25DQ37696315-B68D7AE7-1E3F-4543-AF4C-6CD15BDEF6B8Q37714237-EB42471E-8FA9-4ED3-BBAD-9BCE7B5F6FEBQ37832163-FA09D1ED-CBF2-4893-8117-1B0DAC82BE4DQ37942472-44867FE9-D759-42E8-A627-40ABC4F57920Q37956480-5395D184-4700-45D1-B8A8-EB0F589FAFA1
P2860
Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anticancer therapeutics: targe ...... r CD44, a hyaluronan receptor.
@en
Anticancer therapeutics: targe ...... r CD44, a hyaluronan receptor.
@nl
type
label
Anticancer therapeutics: targe ...... r CD44, a hyaluronan receptor.
@en
Anticancer therapeutics: targe ...... r CD44, a hyaluronan receptor.
@nl
prefLabel
Anticancer therapeutics: targe ...... r CD44, a hyaluronan receptor.
@en
Anticancer therapeutics: targe ...... r CD44, a hyaluronan receptor.
@nl
P2860
P356
P1476
Anticancer therapeutics: targe ...... r CD44, a hyaluronan receptor.
@en
P2093
Francis C Szoka
Virginia M Platt
P2860
P304
P356
10.1021/MP800024G
P407
P577
2008-06-03T00:00:00Z